Zoetis Inc. (NYSE:ZTS) Shares Purchased by Summit Trail Advisors LLC

Summit Trail Advisors LLC lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 10.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,337 shares of the company’s stock after acquiring an additional 623 shares during the quarter. Summit Trail Advisors LLC’s holdings in Zoetis were worth $1,099,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its holdings in Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after acquiring an additional 3,244,074 shares during the last quarter. Sarasin & Partners LLP boosted its holdings in shares of Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after buying an additional 1,904,899 shares during the period. Swedbank AB purchased a new position in Zoetis during the 1st quarter worth approximately $210,815,000. Public Employees Retirement Association of Colorado purchased a new position in shares of Zoetis during the fourth quarter valued at $242,757,000. Finally, CIBC Private Wealth Group LLC increased its holdings in shares of Zoetis by 122.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock valued at $285,923,000 after purchasing an additional 797,884 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ZTS. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research lifted their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Zoetis has an average rating of “Buy” and a consensus price target of $220.38.

Zoetis Stock Performance

NYSE:ZTS opened at $192.64 on Friday. The stock has a market capitalization of $87.90 billion, a P/E ratio of 37.12, a price-to-earnings-growth ratio of 2.98 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a 50 day moving average of $184.70 and a 200-day moving average of $174.40.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter in the previous year, the firm earned $1.41 earnings per share. The business’s revenue was up 8.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.